Long-term outcomes of patients with Hepatitis C virus-related liver transplantation in a high-volume transplant center

Long-term outcomes of patients with Hepatitis C virus-related liver transplantation in a high-volume transplant center | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Long-term outcomes of patients with Hepatitis C virus-related liver transplantation in a high-volume transplant center Engin Ataman, Murat Harputluoglu, Yılmaz Bilgic, Harika Gözde Gözükara, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7629220/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 29 Apr, 2026 Read the published version in BMC Gastroenterology → Version 1 posted 12 You are reading this latest preprint version Abstract Aim HCV is a major indication for liver transplantation (LT) in Europe, America, Australia and Japan. Virological recurrence after HCV-related LT is almost inevitable.We aimed to presantation long-term outcomes of patients LT due to hepatitis C. Materials and Methods We included 98 patients who had LT because of HCV-related liver disease at XXXXXXX University Faculty of Medicine between 2007 and 2022. The survival and recurrence rates of HCV patients and the factors that affected survival and recurrence were investigated. Treatment responses, long-term outcomes in patients had recurence were also analyzed. Results The average post-transplant survival time of 98 patients who had LT due to HCV was 11.91 ± 0.56 years, and 1, 3, 5,10-year survival rates were 95.7%, 88.3%, 82.2% ,75%.The HCV recurrence rate after transplantation was 50%. HCV-RNA positivity and HCV treatment before transplantation were statistically significant factors affecting recurrence. In recurrent patients, the highest rate of sustained virological response at 6 months (100%) was achieved with Maviret (100 mg glecaprevir − 40 mg pibrentasvir). We didn’t find any difference in survival rates between those with and without recurrence.Our findings suggest that survival rates after LT in HCV patients are satisfactory. Conclusion In addition, these results suggest that although the recurrence rate after transplantation is high, with effective treatments, patients with recurrence have a long survival time similar to patients without recurrence. Hepatitis C virus liver transplantation recurrence Main points 1- HCV can cause acute and chronic hepatitis with decompensated liver disease, cirrhosis and hepatocellular carcinoma (HCC). 2- The average post-transplant survival time of 98 patients who underwent LT due to HCV was 11.91 ± 0.56 years, 1, 3, 5 and 10-year survival rates were 95.7%, 88.3%, 82.2% , 75%. 3-Our results suggest that although the recurrence rate after transplantation is high, with effective treatments, patients with recurrence have a long survival time similar to patients without recurrence. INTRODUCTION HCV causes acute and chronic hepatitis, including liver cirrhosis and cancer( 1 ). Hepatocellular carcinoma (HCC) is fifth most common tumor and the third cause of death-related by canser in the world.( 2 ) The WHO called for the elimination of HCV as a public health threat by 2030 in 2016. Fifty-seven million person were living with HCV and 300,000 HCV-related deaths occurred annually in 2020( 3). Main indication for liver transplantation (LT) in Europe, America, Australia and Japan is HCV ( 4 ). Virological recurrence after HCV-related LT is almost inevitable. Nearly 30% of HCV-infected recipients die. They lose their allografts or they develop cirrhosis due to hepatitis C recurrence by the fifth postoperative year and this rate increases as the follow-up period increases. Strategies to minimize the frequency of severe HCV recurrence include avoiding elderly donors, early diagnosis/treatment of cytomegalovirus and minimizing immunosuppression, pulsed corticosteroid treatment of acute cell rejection and particularly T-cell-depleting therapies ( 5). We aimed to presantation long-term outcomes of HCV patients who had LT. MATERIALS AND METHODS We included 98 HCV patients who had LT at XXXXX University Faculty of Medicine between 2007 and 2022. Before starting the study, we received ethical approval from the Ethics Committee of Inonu University in line with the Declaration of Helsinki (19-03-2024**2024/5697). Information an Informed consent was obtained from all patients.The patients’ pre-transplant and post-transplant HCV treatment, HCV RNA values, alanine transaminase (ALT) values, age, gender, additional diseases before transplantation, HCC development before and after transplantation, HCV genotype, donor gender and transplantation type were retrospectively examined. The frequency of cirrhosis, graft failure or fibrosing cholestatic hepatitis after transplantation, immunosuppressive treatments, rejection and re-transplantation frequencies were investigated. Parameters which could affect overall survival and HCV recurrence after transplantation (pre-transplant HCV-RNA and post-transplant HCV-RNA values, pre-transplant ALT and post-transplant ALT levels, treatments received before and after transplantation, pre- and post-transplant HCC, pre-transplant MELD score and comorbidities, genotype) were also analyzed. Statistical methods Distribution of the qualitative data are shown by count and percentage. Comparisons were made by Pearson’s exact test and Bonferroni adjustment were used for multiple comparisons. Survival analyses were performed using the Kaplan-Meier method and univariate Cox regression analysis. Odds ratios (ORs) were estimated by univariate binary logistic regression. In all analyses the two-tailed significance level was accepted as 0.05. RESULTS There was 59 males and 39 females. Clinical and the demographic information of patients who underwent LT due to HCV are shown at Table 1 . 90.8% ( n = 89) of the patients had received LT from living donors. Seventy-five (76.5%) of the patients were alive and 23 (23.5%) had died. Although 78 patients had not received HCV treatment before transplantation, 13 patients had received various treatments. Post-transplant HCV recurrence rate was 50% and all recurrent patients received treatment. The number of patients with HCC before transplantation was 30 (30.6%), and no patients developed HCC recurrence after transplantation. The number of patients who developed graft failure after transplantation was 11, and two patients were re-transplanted. Table 1 Patient demographic and clinical data. n % GENDER FEMALE 59 60.2 MALE 39 39.8 DONOR GENDER FEMALE 34 38.2 MALE 55 61.8 HCV GENOTYPE 1A 3 5.9 1B 41 80.4 2A 1 2.0 3A 4 7.8 4D 1 2.0 5A 1 2.0 TRANSPLANTATION TYPE LIVING DONOR 89 90.8 CADAVERIC 9 9.2 HCV TREATMENT BEFORE TX NO TREATMENT 78 85.7 HARVONI (LEDİPASVİR- SOFOSBUVİR) 5 5.5 EXVIERA (DASABUVIR) 2 2.2 SOVALDI (SOFOSBUVIR 1 1.1 INTERLOKIN ,RIBAVIRIN 4 4.4 PEGASYS (PEGİNTERFERON ALFA-2A) 1 1.1 HCV TREATMENT AFTER TX NO TREATMENT 48 48.9 COPEGUS,PEGASYS(RIBAVIRIN) 3 3.06 MAVIRET(100 MG GLEKAPREVİR − 40 MG PİBRENTASVİR ) 7 7.1 HARVONI(LEDİPASVİR - SOFOSBUVİR) 32 32.6 RIBAVIRIN + SOVOSFOBIR 5 5.1 RIBAVIRIN,INTERFERON 3 3.06 HCC BEFORE TX YES 30 30.6 NO 68 69.4 HCC AFTER TX YES 0 0.0 NO 98 100.0 HCV RNA BEFORE TX NEGATIVE 35 48.6 POSITIVE 37 51.4 HCV RNA AFTER TX NEGATIVE 34 60.7 POSITIVE 22 39.3 HCV RECCURENCE YES 49 50.0 NO 49 50.0 ADDITIONAL DISEASES NO DISEASES 51 52.0 HYPOTHYROIDISM 9 9.2 DIABETES MELLITUS 9 9.2 HYPERTENSION 11 11.2 HEPATITIS B VIRUS 6 6.1 OTHERS 12 12.2 SVR V/Y YES 56 90.3 NO 6 9.7 SVR 3AY YES 52 83.9 NO 10 16.1 SVR 6AY YES 56 90.3 NO 6 9.7 RE-TRANSPLANTATİON YES 2 2.0 NO 96 98.0 CIRRHOSIS OR GRAFT FAILURE YES 11 11.2 NO 87 88.8 FIBROSING CHOLESTATIC HEPATITIS YES 11 11.2 NO 87 88.8 CMV NEGATIVE 95 99.0 POSITIVE 1 1.0 IMMUNSUPRESIVE TREATMENT NO 1 1.0 PROGRAF CELLCEPT 32 32.7 PROGRAF(TAKROLİMUS) 49 50.0 CERTAIN(EVORILIMUS) 6 6.1 CELLCEPT(MİKOFENOLİK ASİT) 7 7.1 SANDIMUN(SİKLOSPORİN) 3 3.1 RITUKSİMAB YES 0 0.0 NO 98 100.0 REJECTION YES 6 6.1 NO 92 93.9 REJ-PULSE STEROİD YES 4 4.1 NO 94 95.9 The average post-transplant survival time of the 98 patients who had transplantation due to HCV was 11.91 ± 0.56 years, and 1, 3, 5, 10-year survival rates were 95.7%, 88.3%, 82.2%, 75%. The overall survival and disease-free survival rates are shown in Table 2 . Table 2 The overall survival and disease free survival rates at 1,3, 5 and 10 years. Overall survival (n = 98) Disease free survival (n = 98) Survival of patients with recurrence (n = 49) Survival (mo.) Mean ± SE 145.01 ± 6.79 70.46 ± 7.44 162.44 ± 7.50 Cumulative survival rate 1 year 95.7% 78.7% 98.0% 3 years 88.3% 54.3% 91.8% 5 years 83.5% 39.6% 91.8% 10 years 75.0% NA 88.7% When the factors affecting the survival of patients were analyzed, no statistically significant factors were identified (Table 3 ). The post-transplant HCV recurrence rate was 50%. When we analyzed which factors affected recurrence, it was found that pre-transplant HCV-RNA positivity and pre-transplant HCV treatment had a statistically significant effect (Table 4 ). When analyzing which factors affected survival in recurrent patients, it was found that similar to the factors affecting recurrence, pre-transplant HCV-RNA positivity and pre-transplant HCV treatment had a statistically significant effect (Table 5 ). Table 3 Cox regression survival analysis (All patients) Univariate Cox regression HR (95% CI) HR p-value Pre-TX HCV rna Negative (n = 35) reference Positive (n = 36) 0.998 (0.361–2.761) 0.996 RECİPİENT DM Yes (n = 15) Reference No (n = 75) 3.267 (0.434–24.569) 0.250 ADDITIONAL DISEASES No (n = 48) Reference Yes (n = 46) 1.067 (0.444–2.565) 0.884 Pre-TX HCC No (n = 68) Reference Yes (n = 30) 1.515 (0.601–3.818) 0.378 Pre-TX HCV treatment Yes (n = 13) Reference No (n = 74) 1.133 (0.257–4.987) 0.869 Pre-TX MELD (n = 98) 0.937 (0.846–1.039) 0.218 Pre-TX ALT (n = 98) 0.999 (0.995–1.003) 0.693 Post-TX ALT (n = 98) 1.001 (1.000-1.003) 0.061 Table 4 Logistic regression analysis for reccurence. Univariate Logistic regression OR (95% CI) OR p-value Pre-TX HCV RNA Negative (n = 35) Reference Positive (n = 37) 12.444 (4.068–38.065) < 0.001 RECIPIENT DM Yes (n = 19) Reference No (n = 79) 1.233 (0.408–3.728) 0.710 ADDITIONAL DISEASES No (n = 51) reference Yes (n = 47) 0.475 (0.212–1.064) 0.070 Pre-TX HCC No (n = 68) reference Yes (n = 30) 1.212 (0.513–2.866) 0.661 Pre-TX HCV treatment Yes (n = 13) reference No (n = 78) 16.364 (2.026-132.148) 0.009 Pre-TX MELD (n = 98) 0.976 (0.911–1.046) 0.500 Pre-TX ALT (n = 98) 1.000 (0.997–1.003) 0.951 Post-TX ALT (n = 98) 0.998 (0.995-1.000) 0.097 Table 5 Cox regression survival analysis (recurrence patients) Univariate Cox regression HR (95% CI) HR p-value Pre-TX HCV rna Negative (n = 7) reference Positive (n = 28) 27.866 (0.000-7477973) 0.602 RECIPIENT DM Yes (n = 7) reference No (n = 41) 25.749 (0.001-1139815) 0.552 ADDITIONAL DISEASES No (n = 30) reference Yes (n = 19) 0.348 (0.039–3.128) 0.346 Pre-TX HCC No (n = 33) reference Yes (n = 16) 1.577 (0.261–9.543) 0.620 Pre-TX HCV treatment Yes (n = 1) reference No (n = 45) 0.104 (0.012–0.943) 0.044 Pre-TX MELD (n = 49) 0.927 (0.748–1.147) 0.484 Pre-TX ALT (n = 49) 1.000 (0.994–1.006) 0.924 Post-TX ALT (n = 49) 0.999 (0.991–1.008) 0.862 The long-term results of recurrent patients were as follows; two patients (4.1%) were re-transplanted, three patients (6.1%) developed cirrhosis or graft failure, five patients (10.2%) developed fibrosing cholestatic hepatitis and four patients (8.2%) developed rejection. In terms of the treatments given after transplantation to patients with recurrence, the highest rate of sustained virological response (SVR) at 24 weeks (100%) was achieved with 100 mg glecaprevir − 40 mg pibrentasvir treatment. The SVR at 24 weeks (SVR24) was achieved in 44 of 49 patients (89.7%). Other treatment rates were 96.6% with Harvoni (ledipasvir - sofosbuvir), 80% with sofosbuvir + ribavirin, and 66.7% with peginterferon alfa-2a), respectively (Table 6 ). The median recurrence time was 18.3 months (1–102.5 months). There was no important difference in survival between those with recurrence and those without recurrence. There was no post tx recurence who received pre-tx DAA treatment. While there was no recurrence in those who received DAA treatment before transplantation, recurrence occurred after an average of 18.3 months in those who did not. Table 6 SVR rates in the recurrent patients. copegus, pegasys mavıret harvoni rıbavirin+ sovosfobir pegasy, ribavirin, interferon p-value SVR Yes 2 (66.7) 7 (100) 31 (96.9) 4 (80.0) a,b 0 (0) a 0.066 No 1 (33.3) 0 (0) 1 (3.1) 1 (20.0) a,b 2 (100) a SVR 3 mo Yes 2 (66.7) a,b 7 (100) b 28 (87.5) b 3 (60.0) a,b 0 (0) a 0.015 No 1 (33.3) a,b 0 (0) b 4 (12.5) b 2 (40.0) a,b 2 (100) a SVR 6 mo Yes 2 (66.7) a,b 7 (100) b 31 (96.9) b 4 (80.0) a,b 0 (0) a 0.002 No 1 (33.3) a,b 0 (0) b 1 (3.1) b 1 (20.0) a,b 2 (100) a Total 3 (6.1) 7 (14.3) 32 (65.3) 5 (10.2) 2 (4.1) 49 (100) *Superscript letters indicate statistical significance between column proportions ** Data are presented as n (%) DISCUSSION Before DAA ,Zekry A. et all reported in their study of 182 patients with HCV, 3 ,5 year survival rates after LT were reported as 85%, 76%, respectively ( 6 ). In a study by Bonaccorsi-Riani E et al., 3-month and 1- and 5-year patient survival rates were 100%, 93% and 76%, respectively (7 ). In a study by Kim JM et al., the 1, 3, and 5 year cumulative patient survival rates were 78.8%, 75.3%, 73.1%. The same study showed that recipient age ≥ 60 years, deceased donor liver transplantation, biopsy-proven acute rejection and cyclosporine use, were independent prognostic factors for mortality ( 8 ). In HCV patients, the 5-year patient survival rate after transplantation was reported to be 76% in the United Network for Organ Sharing Database and 65% in the European Liver Transplant Registry ( 9 , 10 ). Recently, a nationwide live donor liver transplantation study in Japan reported 72% for a 5-year patient survival rate( 9 ). In the current study, the 1, 3, 5 ,10-year survival rates were 95.7%, 88.3%, 82.2% and 75%, respectively. We did not detect any significant factors affecting survival rates. After DAA Lim N reported 6,12,24 months HCC-free survival were 96.2, 96.2, and 78.8% in the DAA group, ( 11 ). In a study designed by Kauffman the median follow-up after LT was 55 months, the graft survival was 100%. at one and three years. Fifty-six patients received DAA after the LT with 98% SVR-12.( 12). Arora et all.. reported One-year patient survival and liver graft among HCV LT improved in DAA era (90% vs. 86%, 92% vs. 88%, P < 0.0001).( 13 ). Our findings suggest that post-transplant survival rates are satisfactory when compared with previous studies. Additionally, our results suggest that LT should be considered when necessary in this patient group. Detecting HCV recurrence early is important in terms of early initiation of treatment and good response in patients with recurrence. Successful treatment of recurrent HCV is associated with improved overall survival and reduced liver-related mortality( 14 ). In our study, the recurrence rate was 50%. When we analyzed which factors affected recurrence, it was found that pre-transplant HCV-RNA positivity and pre-transplant HCV treatment had a statistically significant effect. In the study conducted by Kim JM, the recurrence rate was 57.4% ( 8 ). Burra P and colleagues reported that histological recurrence developed in 80% of patients, cirrhosis in 30%, and fibrosing cholestatic jaundice in 2–5% within 5 years after transplantation,. In the same study,donor and recipient characteristics, viral status, surgical procedure and immunosuppression regimen applied were found to be associated with recurrence ( 15 ). Samonakis et al. reported that immunosuppression is an important factor for accelerated HCV recurrence ( 16 ). Terrault et al. reported that reinfection of the graft with HCV is universal in all HCV rNA PCR positif patients at transplantation, and the progression of fibrosis has been reported to be faster compared to patients who hadn’t transplantation ( 17 ). It was determined that pre-transplant viral load was a significant factor related to recurrence. Therefore, our results suggest that pre-transplant viral load plays an important role in post-transplant HCV recurrence in our study. After the introduction of direct-acting antivirals (DAAs) in 2013 significant advances have been made in the treatment of HCV (improved efficacy,shorter treatment,good tolerability).( 18 ) In this study, of the treatments given after transplantation to patients with recurrence, the highest rate of SVR24 (100%) was achieved with (100 mg glecaprevir − 40 mg pibrentasvir) treatment. Other treatment rates were 96.6% with ( ledipasvir- sofosbuvir) 80% with sofosbuvir + ribavirin and 66.7% with (peginterferon alfa-2a), respectively. SVR24 was achieved in 44 of 49 patients (89.7%). The median of recurrence was 18.3 months. Before DAA ,Kim JM et al. reported that patients with SVR had higher survival rates than patients without SVR, and there was no importnat difference in patient survival between the two groups ( 8 ). In a study by Verna et al., post-transplant SVR12 was 67% ( 19 ). Sofosbuvir and simeprevir combination was evaluated in 68 LT patients enrolled in the study of real-life HCV TARGET. The SVR12 rate was 90% and was more in cirrhotic patients ( 20 ). Kwo et al. reported that in a study of 34 patients (Ombitasvir-ABT-450/, receiving dasabuvir), 33 of these patients achieved a 97% SVR at 12 and 24 weeks after treatment ( 21 ). In another study, Choudhary et al. reported 89.4% rate at 68/76 patients achieved SVR at 12 weeks ( 22 ). 1730 patients treated with a sofosbuvir-based interferon-free combination reported 90% SVR in post-transplant patients in a systemic review( 23 ). After DAA ,in a study fo Beinhardt s, A total of 62 OLT recipients received RBV-free treatment with second-generation DAA combinations,SVR12 was 97% (60/62 ( 24 ). In a study designed by Iacob S included 89 patients patients with genotype 1 (GT1) recurrent hepatitis C after LT, 13 patients received sofosbuvir/ledipasvir+/-ribavirin and seventy six received ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin. VR was 100% and SVR12 was 97.7%. ( 25 )In CORAL-I study ( 26 )the combination of OBV/PTV/r + DSV + RBV for 24 weeks was investigated in 34 LT recipients with GT1 infection and achieved 97% SVR12. The ALLY-1 study [16], combining sofosbuvir + daclatasvir + ribavirin (SOF + DAC ± RBV), showed 94% SVR12 (30% patients with liver graft cirrhosis). The Italian Compassionate use of Sofosbuvir (ITACOPS) [27] showed a 86.7% SVR rate at SOF/RBV treatment and 98.3% in patients receiving SOF/RBV for 24 weeks, when simeprevir or DAC was added. In a study designed by Liu 226 patients were divided in too two groups, pre (Group A) and post (Group B) 2014 to reflect the introduction of DAAs. The rate of SVR at 2 years of was 86.7% in group B and 15.4% group A.(28). Our findings suggest that 100 mg glecaprevir − 40 mg pibrentasvir therapy is the most effective treatment for post-transplant relapse. Our results also show that sofosbuvir-based regimens are very effective treatments. There was no important difference in survival rates between those with and without recurrence. This finding also indicates that antiviral treatments are very effective in patients had recurrence after transplantation. In our study long-term results of relapsed patients were as follows: two patients (4.1%) were re-transplanted, three patients (6.1%) developed cirrhosis or graft failure, five patients (10.2%) developed fibrosing cholestatic hepatitis and four patients (8.2%) developed rejection. Burra P et al. reported that 30% of relapsed patients developed cirrhosis and 2%–5% developed fibrosing cholestatic jaundice ( 15 ). Dumortier reported an estimated incidence of HCV-related fibrosing cholestatic jaundice after LT of 2%–14% ( 29). Our findings suggest that the most common long-term problem in patients had recurrent HCV after transplantation is fibrosing cholestatic hepatitis. Factors limiting our study were that patients came from different cities, which prevented us from accessing some information before and after transplantation. In conclusion, our findings suggest that survival rates after LT in HCV patients are satisfactory. In addition, our results suggest that although the recurrence rate after transplantation is high, with effective treatments, patients with recurrence have a long survival time similar to patients without recurrence. Abbreviations DAAs :direct-acting antivirals LT: liver transplantation HCC:hepatocellular carcinoma ALT :alanine transaminase SVR:sustained virological response Declarations Acknowledgements Not applicable. Author contributions EA participated in data analysis and interpretation and article drafting. EA,MH,YB participated in data analysis and interpretation and article drafting. SY,VI,EA participated in data analysis and interpretation and article drafting. MA,HGG participated in data analysis and interpretation and in critically revising the manuscript for important intellectual content. EA,MH participated in the study design, data analysis and interpretation and gave final approval for publication. All authors read and approved the final manuscript. Funding Not applicable. Availability of data and materials The datasets used and/or analysed during the current study available from the corresponding author on reasonable request. Ethics approval and consent to participate This study was conducted according to the principles expressed in the Declaration of Helsinki and approved by the Ethics Committee of Inonu University in line with the Declaration of Helsinki (19-03-2024**2024/5697). Information an Informed consent was obtained from all patients. Consent for publication Not applicable. Competing interests No potential conflict of interest was reported by the author. References Gökahmetoğlu S, Polat C, Atalay MA, Sezgin GC, Ergör G, Aygen B, Gürsoy Ş, Abacıoğlu YH. Healthcare-Related HCV Genotype 4d Infections in Kayseri, Turkey. Turk J Gastroenterol. 2022 Nov;33(11):964-970. doi: 10.5152/tjg.2022.21822. PMID: 36098364; PMCID: PMC9797710. Akarca US, Unsal B, Sezgin O, Yalcin K, Akdogan M, Gonen C, Gunduz F, Ozenirler S, Sonsuz A, Dincer D, Tekin SB, Yucel I, Akbulut H, Alkım C, Ozyilkan O, Baygul A, Cevik ZM, Idilman R, Study Group OBOKR. Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study. Turk J Gastroenterol. 2021 Dec;32(12):1019-1028. doi: 10.5152/tjg.2021.201171. PMID: 34876392; PMCID: PMC8975510 Martinello M, Solomon SS, Terrault NA, Dore GJ. Hepatitis C. Lancet. 2023 Sep 23;402(10407):1085-1096. doi: 10.1016/S0140-6736(23)01320-X. PMID: 37741678.) Berenguer M, Liver transplant 2002;8:S14. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug;9(8):1707-13. doi: 10.1111/j.1600-6143.2009.02702.x. Epub 2009 Jun 16. PMID: 19538491. Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, Gane EJ, McCaughan GW; Australian and New Zealand Liver Transplant Clinical Study Group. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl. 2003 Apr;9(4):339-47. doi: 10.1053/jlts.2003.50063. PMID: 12682883. Bonaccorsi-Riani E, Sempoux C, Piette N, Julliard O, Kabamba B, Ciccarelli O, Roggen F, De Reyck C, Hassoun Z, Lerut J. Impact of steroid-avoidance immunosuppression on long-term outcome after liver transplantation for HCV cirrhosis: the need for well documented long-term follow-up. Acta Gastroenterol Belg. 2012 Dec;75(4):411-8. PMID: 23402084. Kim JM, Lee KW, Song GW, Jung BH, Lee HW, Yi NJ, Kwon CH, Hwang S, Suh KS, Joh JW, Lee SK, Lee SG. Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study. Ann Surg Treat Res. 2016 Jan;90(1):36-42. doi: 10.4174/astr.2016.90.1.36. Epub 2015 Dec 29. PMID: 26793691; PMCID: PMC4717607. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95:755–760. [PubMed] [Google Scholar][Ref list] Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR) J Hepatol. 2012;57:675–688. [PubMed] [Google Scholar][Ref list] Lim N, Singh D, Jackson S, Lake JR. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy. Gastrointest Tumors. 2020 Oct;7(4):134-143. doi: 10.1159/000510341. Epub 2020 Sep 14. PMID: 33173777; PMCID: PMC7590751. Kauffman-Ortega E, Ruiz-Manriquez J, Olivas-Martinez A, Campos-Murguía A, Flores-García NC, Márquez-Guillén E, López-Yáñez S, Sánchez-Ávila F, Toapanta-Yanchapaxi L, Paez-Zayas VM, García-Juárez I. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort. Arch Med Res. 2021 Oct;52(7):713-718. doi: 10.1016/j.arcmed.2021.04.003. Epub 2021 May 7. PMID: 33966917. Arora SS, Axley P, Ahmed Z, Satapathy SK, Wong R, Kuo YF, Singal AK. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study. Transpl Int. 2019 Aug;32(8):854-864. doi: 10.1111/tri.13424. Epub 2019 Mar 26. PMID: 30866110. Guillouche P, Feray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther. 2011;33:163–174. [PubMed] [Google Scholar][Ref list] Burra P, De Martin E, Zanetto A, Senzolo M, Russo FP, Zanus G, Fagiuoli S. Hepatitis C virus and liver transplantation: where do we stand? Transpl Int. 2016 Feb;29(2):135-52. doi: 10.1111/tri.12642. Epub 2015 Aug 11. PMID: 26199060. Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol. 2012 Apr;56(4):973-83. doi: 10.1016/j.jhep.2011.06.031. Epub 2011 Sep 29. PMID: 21963518. Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown Jr RS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007;13:122–129. (Çekin AH, Güner R, Çağkan İnkaya A, Oğuz D, Özdemir O, Tabak ÖF. Modeling the Health Economic Burden of Hepatitis C Virus Infection in Turkey: Cost-Effectiveness of Targeted Screening. Turk J Gastroenterol. 2023 Oct;34(10):1062-1070. doi: 10.5152/tjg.2023.22749. PMID: 37565793; PMCID: PMC10645295.) Verna EC, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, Fox AN, Dove LM, Brown RS. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver Int. 2015;35:510–517. [PubMed] [Google Scholar] [Ref list] Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim KJ, Morelli G, Feld JJ, Brown RS, Frazier LM, et al. Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + Ribavirin in Patients with Genotype 1: Interim Results of a Prospective, Observational Study. Hepatology. 2014;60(S1):660A. [Google Scholar] [Ref list] Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR Jr, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18;371(25):2375-82. doi: 10.1056/NEJMoa1408921. Epub 2014 Nov 11. PMID: 25386767. Choudhary NS, Saigal S, Gautam D, Saraf N, Rastogi A, Goja S, Bhangui P, Soin AS. Efficacy And Safety of Sofosbuvir Based Regimens For Treatment of Hepatitis C Recurrence After Living Donor Liver Transplantation: An Experience From India. J Clin Exp Hepatol. 2018 Jun;8(2):121-124. doi: 10.1016/j.jceh.2017.08.004. Epub 2017 Sep 1. PMID: 29892173; PMCID: PMC5992320. Qu Y., Guo Y., Li T. Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients. J Gastroenterol Hepatol. 2017;32:740–748.[PubMed] [Google Scholar] [Ref list] Beinhardt S, Al-Zoairy R, Kozbial K, Stättermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, Graziadei I, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver Int. 2018 Jul;38(7):1188-1197. doi: 10.1111/liv.13652. Epub 2018 Jan 31. PMID: 29197145 Iacob S, Cerban R, Pietrareanu C, Ester C, Iacob R, Gheorghe C, Popescu I, Gheorghe L. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation. J Gastrointestin Liver Dis. 2018 Jun;27(2):139-144. doi: 10.15403/jgld.2014.1121.272.100. PMID: 29922758 Kwo PY, Mantry PS, Coaldey E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371:2375-2382 Kwo PY, Mantry PS, Coaldey E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371:2375-2382 oi:10.1056/NEJMoa140892 Carrai P, Morelli C, Cordone G, et al. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transpl Int 2017;30:1253-1265. doi:10.1111/tri.13018 Liu A, Angirekula M, Elhawary A, Mara K, Kulai T, Leise M, Watt KD. Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response. Clin Transplant. 2023 Oct;37(10):e15050. doi: 10.1111/ctr.15050. Epub 2023 Jun 17. PMID: 37329298. Dumortier J, Boillot O, Scoazec JY. Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. World J Gastroenterol. 2014 Aug 28;20(32):11069-79. doi: 10.3748/wjg.v20.i32.11069. PMID: 25170196; PMCID: PMC4145750. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 29 Apr, 2026 Read the published version in BMC Gastroenterology → Version 1 posted Editorial decision: Revision requested 16 Oct, 2025 Reviews received at journal 16 Oct, 2025 Reviews received at journal 11 Oct, 2025 Reviews received at journal 09 Oct, 2025 Reviewers agreed at journal 01 Oct, 2025 Reviewers agreed at journal 01 Oct, 2025 Reviewers agreed at journal 28 Sep, 2025 Reviewers invited by journal 28 Sep, 2025 Editor invited by journal 25 Sep, 2025 Editor assigned by journal 24 Sep, 2025 Submission checks completed at journal 24 Sep, 2025 First submitted to journal 16 Sep, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7629220","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":526503808,"identity":"87af5bbc-f23f-4fbb-862e-1b485feaf80f","order_by":0,"name":"Engin Ataman","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABD0lEQVRIie3PsUoDMRjA8RShXVK6ScpBfILCdwbExd6rJBx4S5AbO3To1C7iXLD4EkLmQOCmk+IW0OEOwanDgSAOIjatY3NdHfJfciT340sQCoX+afpv7VR8sv/W1XECbj2BqtQIux1+fNCOdIf1fE9QGxlEi2eTT7/PRoungoiHV5qcmno7ZUxHs8NkuCpzsywgVuVNeinUO8PRNWxJyi6050ZWcoO70FFaxlYoI24j7ogWykOSHfmBRK03QMTKkaxpJUAybfpzEMrKcyJmjsj2KcRKZPp3LFV2w4AXhuEXmWsO/rcMltnbB/6kV2ot4/pramjvPntsmsmY+ghCGA5e2Pe7q1e1nYZCoVAIoV8R7GtDCmyWiwAAAABJRU5ErkJggg==","orcid":"","institution":"Inonu University","correspondingAuthor":true,"prefix":"","firstName":"Engin","middleName":"","lastName":"Ataman","suffix":""},{"id":526503809,"identity":"4c13fbfd-a563-4f09-ac9d-0f35d2a88f60","order_by":1,"name":"Murat Harputluoglu","email":"","orcid":"","institution":"Inonu University","correspondingAuthor":false,"prefix":"","firstName":"Murat","middleName":"","lastName":"Harputluoglu","suffix":""},{"id":526503810,"identity":"37eabf71-5935-454c-bcf5-af3bab16af18","order_by":2,"name":"Yılmaz Bilgic","email":"","orcid":"","institution":"Inonu University","correspondingAuthor":false,"prefix":"","firstName":"Yılmaz","middleName":"","lastName":"Bilgic","suffix":""},{"id":526503811,"identity":"37cd5af3-8182-4235-a365-35461d5d7e47","order_by":3,"name":"Harika Gözde Gözükara","email":"","orcid":"","institution":"Inonu University","correspondingAuthor":false,"prefix":"","firstName":"Harika","middleName":"Gözde","lastName":"Gözükara","suffix":""},{"id":526503812,"identity":"9e30ad15-d5b6-4b6f-b860-f431d97bc579","order_by":4,"name":"Murat Aladağ","email":"","orcid":"","institution":"Inonu University","correspondingAuthor":false,"prefix":"","firstName":"Murat","middleName":"","lastName":"Aladağ","suffix":""},{"id":526503813,"identity":"334e539a-8878-410b-ac67-2beabfb8a4c3","order_by":5,"name":"Volkan İnce","email":"","orcid":"","institution":"Inonu University","correspondingAuthor":false,"prefix":"","firstName":"Volkan","middleName":"","lastName":"İnce","suffix":""},{"id":526503814,"identity":"3e400b5f-1ac8-4c7d-8dc3-05c9e6f4efc6","order_by":6,"name":"Sezai Yılmaz","email":"","orcid":"","institution":"Inonu University","correspondingAuthor":false,"prefix":"","firstName":"Sezai","middleName":"","lastName":"Yılmaz","suffix":""}],"badges":[],"createdAt":"2025-09-16 10:23:30","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7629220/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7629220/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12876-026-04678-9","type":"published","date":"2026-04-29T15:57:13+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":93146714,"identity":"a2f4f054-c5a6-466e-a867-a3ff5679ca2f","added_by":"auto","created_at":"2025-10-09 13:57:24","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":43673,"visible":true,"origin":"","legend":"","description":"","filename":"hcv2032025.docx","url":"https://assets-eu.researchsquare.com/files/rs-7629220/v1/0a18842f46d7cdb16233f020.docx"},{"id":93145890,"identity":"8f551f90-f2af-4d36-aced-5e15d6eb4eca","added_by":"auto","created_at":"2025-10-09 13:49:24","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":33458,"visible":true,"origin":"","legend":"","description":"","filename":"hcvtables2025.docx","url":"https://assets-eu.researchsquare.com/files/rs-7629220/v1/91687c6c93c8b3f7b96fedd9.docx"},{"id":93145892,"identity":"bd378ef7-573f-4aa8-a416-56dd0b38be87","added_by":"auto","created_at":"2025-10-09 13:49:25","extension":"json","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":8917,"visible":true,"origin":"","legend":"","description":"","filename":"7302679b13fd4068a1d0017b078b1b62.json","url":"https://assets-eu.researchsquare.com/files/rs-7629220/v1/6e6e94419e15e7fc9d8d5220.json"},{"id":93145891,"identity":"285df326-6dce-49a9-a51e-33958b18f544","added_by":"auto","created_at":"2025-10-09 13:49:25","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":127302,"visible":true,"origin":"","legend":"","description":"","filename":"7302679b13fd4068a1d0017b078b1b621enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7629220/v1/7223c3b7027b0e851108a67c.xml"},{"id":93146715,"identity":"e43b7dd7-3d0a-4155-86fe-f4ff3ee6ff5b","added_by":"auto","created_at":"2025-10-09 13:57:25","extension":"xml","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":125791,"visible":true,"origin":"","legend":"","description":"","filename":"7302679b13fd4068a1d0017b078b1b621structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7629220/v1/84e72e2fabb28b319f2617a9.xml"},{"id":93145895,"identity":"49d614f9-bf68-4391-9ec8-1d024e19fac3","added_by":"auto","created_at":"2025-10-09 13:49:25","extension":"html","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":134741,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7629220/v1/e3cdf454e91591fb5ad84904.html"},{"id":108437568,"identity":"7638da42-b582-43fd-a0de-00af64ac85e1","added_by":"auto","created_at":"2026-05-04 15:59:25","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":479160,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7629220/v1/5f6f071a-3acb-4b41-a147-65cde30ddf84.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Long-term outcomes of patients with Hepatitis C virus-related liver transplantation in a high-volume transplant center","fulltext":[{"header":"Main points","content":"\u003cp\u003e1-\u0026nbsp;HCV can cause acute and chronic hepatitis with decompensated liver disease, cirrhosis and hepatocellular carcinoma (HCC).\u003c/p\u003e\n\u003cp\u003e2-\u0026nbsp;The average post-transplant survival time of 98 patients who underwent LT due to HCV was 11.91 ± 0.56 years, 1, 3, 5 and 10-year survival rates were 95.7%, 88.3%, 82.2% , 75%.\u003c/p\u003e\n\u003cp\u003e3-Our results suggest that although the recurrence rate after transplantation is high, with effective treatments, patients with recurrence have a long survival time similar to patients without recurrence. \u0026nbsp;\u003c/p\u003e"},{"header":"INTRODUCTION","content":"\u003cp\u003eHCV causes acute and chronic hepatitis, including liver cirrhosis and cancer(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Hepatocellular carcinoma (HCC) is fifth most common tumor and the third cause of death-related by canser in the world.(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e)\u003c/p\u003e\u003cp\u003eThe WHO called for the elimination of HCV as a public health threat by 2030 in 2016. Fifty-seven million person were living with HCV and 300,000 HCV-related deaths occurred annually in 2020( 3).\u003c/p\u003e\u003cp\u003eMain indication for liver transplantation (LT) in Europe, America, Australia and Japan is HCV (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e). Virological recurrence after HCV-related LT is almost inevitable. Nearly 30% of HCV-infected recipients die. They lose their allografts or they develop cirrhosis due to hepatitis C recurrence by the fifth postoperative year and this rate increases as the follow-up period increases. Strategies to minimize the frequency of severe HCV recurrence include avoiding elderly donors, early diagnosis/treatment of cytomegalovirus and minimizing immunosuppression, pulsed corticosteroid treatment of acute cell rejection and particularly T-cell-depleting therapies ( 5).\u003c/p\u003e\u003cp\u003eWe aimed to presantation long-term outcomes of HCV patients who had LT.\u003c/p\u003e"},{"header":"MATERIALS AND METHODS","content":"\u003cp\u003eWe included 98 HCV patients who had LT at XXXXX University Faculty of Medicine between 2007 and 2022. Before starting the study, we received ethical approval from the Ethics Committee of Inonu University in line with the Declaration of Helsinki (19-03-2024**2024/5697). Information an Informed consent was obtained from all patients.The patients\u0026rsquo; pre-transplant and post-transplant HCV treatment, HCV RNA values, alanine transaminase (ALT) values, age, gender, additional diseases before transplantation, HCC development before and after transplantation, HCV genotype, donor gender and transplantation type were retrospectively examined.\u003c/p\u003e\u003cp\u003eThe frequency of cirrhosis, graft failure or fibrosing cholestatic hepatitis after transplantation, immunosuppressive treatments, rejection and re-transplantation frequencies were investigated.\u003c/p\u003e\u003cp\u003eParameters which could affect overall survival and HCV recurrence after transplantation (pre-transplant HCV-RNA and post-transplant HCV-RNA values, pre-transplant ALT and post-transplant ALT levels, treatments received before and after transplantation, pre- and post-transplant HCC, pre-transplant MELD score and comorbidities, genotype) were also analyzed.\u003c/p\u003e\u003cp\u003eStatistical methods\u003c/p\u003e\u003cp\u003eDistribution of the qualitative data are shown by count and percentage. Comparisons were made by Pearson\u0026rsquo;s exact test and Bonferroni adjustment were used for multiple comparisons. Survival analyses were performed using the Kaplan-Meier method and univariate Cox regression analysis. Odds ratios (ORs) were estimated by univariate binary logistic regression. In all analyses the two-tailed significance level was accepted as 0.05.\u003c/p\u003e"},{"header":"RESULTS","content":"\u003cp\u003eThere was 59 males and 39 females. Clinical and the demographic information of patients who underwent LT due to HCV are shown at Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. 90.8% (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;89) of the patients had received LT from living donors. Seventy-five (76.5%) of the patients were alive and 23 (23.5%) had died. Although 78 patients had not received HCV treatment before transplantation, 13 patients had received various treatments. Post-transplant HCV recurrence rate was 50% and all recurrent patients received treatment. The number of patients with HCC before transplantation was 30 (30.6%), and no patients developed HCC recurrence after transplantation. The number of patients who developed graft failure after transplantation was 11, and two patients were re-transplanted.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003ePatient demographic and clinical data.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003en\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003e%\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eGENDER\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eFEMALE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e59\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e60.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eMALE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e39\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e39.8\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eDONOR GENDER\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eFEMALE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e34\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e38.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eMALE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e55\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e61.8\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e\u003cp\u003eHCV GENOTYPE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1A\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e5.9\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1B\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e41\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e80.4\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2A\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e2.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e3A\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e7.8\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e4D\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e2.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e5A\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e2.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eTRANSPLANTATION TYPE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLIVING DONOR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e89\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e90.8\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCADAVERIC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e9\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e9.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e\u003cp\u003eHCV TREATMENT BEFORE TX\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO TREATMENT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e78\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e85.7\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHARVONI (LEDİPASVİR- SOFOSBUVİR)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e5.5\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eEXVIERA (DASABUVIR)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e2.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSOVALDI (SOFOSBUVIR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e1.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eINTERLOKIN ,RIBAVIRIN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e4.4\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePEGASYS (PEGİNTERFERON ALFA-2A)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e1.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e\u003cp\u003eHCV TREATMENT AFTER TX\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO TREATMENT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e48\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e48.9\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCOPEGUS,PEGASYS(RIBAVIRIN)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e3.06\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eMAVIRET(100 MG GLEKAPREVİR \u0026minus;\u0026thinsp;40 MG PİBRENTASVİR )\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e7\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e7.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHARVONI(LEDİPASVİR - SOFOSBUVİR)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e32\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e32.6\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRIBAVIRIN\u0026thinsp;+\u0026thinsp;SOVOSFOBIR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e5.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRIBAVIRIN,INTERFERON\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e3.06\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eHCC BEFORE TX\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e30\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e30.6\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e68\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e69.4\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eHCC AFTER TX\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e98\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e100.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eHCV RNA BEFORE TX\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNEGATIVE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e35\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e48.6\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePOSITIVE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e37\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e51.4\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eHCV RNA AFTER TX\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNEGATIVE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e34\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e60.7\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePOSITIVE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e22\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e39.3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eHCV RECCURENCE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e49\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e50.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e49\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e50.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e\u003cp\u003eADDITIONAL DISEASES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO DISEASES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e51\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e52.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHYPOTHYROIDISM\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e9\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e9.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDIABETES MELLITUS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e9\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e9.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHYPERTENSION\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e11\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e11.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHEPATITIS B VIRUS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e6\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e6.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eOTHERS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e12\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e12.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eSVR V/Y\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e56\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e90.3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e6\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e9.7\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eSVR 3AY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e52\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e83.9\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e10\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e16.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eSVR 6AY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e56\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e90.3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e6\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e9.7\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eRE-TRANSPLANTATİON\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e2.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e96\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e98.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eCIRRHOSIS OR GRAFT FAILURE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e11\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e11.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e87\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e88.8\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eFIBROSING CHOLESTATIC HEPATITIS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e11\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e11.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e87\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e88.8\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eCMV\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNEGATIVE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e95\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e99.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePOSITIVE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e1.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e\u003cp\u003eIMMUNSUPRESIVE TREATMENT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e1.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePROGRAF CELLCEPT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e32\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e32.7\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePROGRAF(TAKROLİMUS)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e49\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e50.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCERTAIN(EVORILIMUS)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e6\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e6.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCELLCEPT(MİKOFENOLİK ASİT)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e7\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e7.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSANDIMUN(SİKLOSPORİN)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e3.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eRITUKSİMAB\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e98\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e100.0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eREJECTION\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e6\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e6.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e92\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e93.9\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eREJ-PULSE STEROİD\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e4.1\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e94\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e95.9\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eThe average post-transplant survival time of the 98 patients who had transplantation due to HCV was 11.91\u0026thinsp;\u0026plusmn;\u0026thinsp;0.56 years, and 1, 3, 5, 10-year survival rates were 95.7%, 88.3%, 82.2%, 75%. The overall survival and disease-free survival rates are shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eThe overall survival and disease free survival rates at 1,3, 5 and 10 years.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"5\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eOverall survival (n\u0026thinsp;=\u0026thinsp;98)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eDisease free survival (n\u0026thinsp;=\u0026thinsp;98)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eSurvival of patients with recurrence (n\u0026thinsp;=\u0026thinsp;49)\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u003cp\u003eSurvival (mo.) Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e145.01\u0026thinsp;\u0026plusmn;\u0026thinsp;6.79\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e70.46\u0026thinsp;\u0026plusmn;\u0026thinsp;7.44\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e162.44\u0026thinsp;\u0026plusmn;\u0026thinsp;7.50\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e\u003cp\u003eCumulative survival rate\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1 year\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e95.7%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e78.7%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e98.0%\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e3 years\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e88.3%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e54.3%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e91.8%\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e5 years\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e83.5%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e39.6%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e91.8%\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e10 years\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e75.0%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eNA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e88.7%\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eWhen the factors affecting the survival of patients were analyzed, no statistically significant factors were identified (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). The post-transplant HCV recurrence rate was 50%. When we analyzed which factors affected recurrence, it was found that pre-transplant HCV-RNA positivity and pre-transplant HCV treatment had a statistically significant effect (Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e). When analyzing which factors affected survival in recurrent patients, it was found that similar to the factors affecting recurrence, pre-transplant HCV-RNA positivity and pre-transplant HCV treatment had a statistically significant effect (Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eCox regression survival analysis (All patients)\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u003cp\u003eUnivariate\u003c/p\u003e\u003cp\u003eCox regression\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eHR\u003c/p\u003e\u003cp\u003e(95% CI)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eHR\u003c/p\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePre-TX HCV rna\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNegative (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ereference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePositive (n\u0026thinsp;=\u0026thinsp;36)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.998 (0.361\u0026ndash;2.761)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.996\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eRECİPİENT DM\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;15)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;75)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e3.267 (0.434\u0026ndash;24.569)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.250\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eADDITIONAL DISEASES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;48)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;46)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1.067 (0.444\u0026ndash;2.565)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.884\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePre-TX HCC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;68)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;30)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1.515 (0.601\u0026ndash;3.818)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.378\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePre-TX HCV treatment\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;13)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;74)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1.133 (0.257\u0026ndash;4.987)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.869\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePre-TX MELD\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;98)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.937 (0.846\u0026ndash;1.039)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.218\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePre-TX ALT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;98)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.999 (0.995\u0026ndash;1.003)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.693\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePost-TX ALT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;98)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1.001 (1.000-1.003)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.061\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eLogistic regression analysis for reccurence.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u003cp\u003eUnivariate\u003c/p\u003e\u003cp\u003eLogistic regression\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eOR\u003c/p\u003e\u003cp\u003e(95% CI)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eOR\u003c/p\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePre-TX HCV RNA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNegative (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePositive (n\u0026thinsp;=\u0026thinsp;37)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e12.444 (4.068\u0026ndash;38.065)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u003cb\u003e\u0026lt;\u0026thinsp;0.001\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eRECIPIENT DM\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;19)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;79)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1.233 (0.408\u0026ndash;3.728)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.710\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eADDITIONAL DISEASES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;51)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ereference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;47)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.475 (0.212\u0026ndash;1.064)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.070\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePre-TX HCC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;68)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ereference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;30)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1.212 (0.513\u0026ndash;2.866)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.661\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePre-TX HCV treatment\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;13)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ereference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;78)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e16.364 (2.026-132.148)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u003cb\u003e0.009\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePre-TX MELD\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;98)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.976 (0.911\u0026ndash;1.046)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.500\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePre-TX ALT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;98)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1.000 (0.997\u0026ndash;1.003)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.951\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePost-TX ALT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;98)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.998 (0.995-1.000)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.097\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eCox regression survival analysis (recurrence patients)\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u003cp\u003eUnivariate\u003c/p\u003e\u003cp\u003eCox regression\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eHR\u003c/p\u003e\u003cp\u003e(95% CI)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eHR\u003c/p\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePre-TX HCV rna\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNegative (n\u0026thinsp;=\u0026thinsp;7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ereference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePositive (n\u0026thinsp;=\u0026thinsp;28)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e27.866 (0.000-7477973)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.602\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eRECIPIENT DM\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ereference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;41)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e25.749 (0.001-1139815)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.552\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eADDITIONAL DISEASES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;30)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ereference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;19)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.348 (0.039\u0026ndash;3.128)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.346\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePre-TX HCC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;33)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ereference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;16)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1.577 (0.261\u0026ndash;9.543)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.620\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePre-TX HCV treatment\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes (n\u0026thinsp;=\u0026thinsp;1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ereference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo (n\u0026thinsp;=\u0026thinsp;45)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.104 (0.012\u0026ndash;0.943)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u003cb\u003e0.044\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePre-TX MELD\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;49)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.927 (0.748\u0026ndash;1.147)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.484\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePre-TX ALT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;49)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1.000 (0.994\u0026ndash;1.006)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.924\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePost-TX ALT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;49)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.999 (0.991\u0026ndash;1.008)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.862\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eThe long-term results of recurrent patients were as follows; two patients (4.1%) were re-transplanted, three patients (6.1%) developed cirrhosis or graft failure, five patients (10.2%) developed fibrosing cholestatic hepatitis and four patients (8.2%) developed rejection. In terms of the treatments given after transplantation to patients with recurrence, the highest rate of sustained virological response (SVR) at 24 weeks (100%) was achieved with 100 mg glecaprevir \u0026minus;\u0026thinsp;40 mg pibrentasvir treatment. The SVR at 24 weeks (SVR24) was achieved in 44 of 49 patients (89.7%). Other treatment rates were 96.6% with Harvoni (ledipasvir - sofosbuvir), 80% with sofosbuvir\u0026thinsp;+\u0026thinsp;ribavirin, and 66.7% with peginterferon alfa-2a), respectively (Table\u0026nbsp;\u003cspan refid=\"Tab6\" class=\"InternalRef\"\u003e6\u003c/span\u003e). The median recurrence time was 18.3 months (1\u0026ndash;102.5 months). There was no important difference in survival between those with recurrence and those without recurrence. There was no post tx recurence who received pre-tx DAA treatment. While there was no recurrence in those who received DAA treatment before transplantation, recurrence occurred after an average of 18.3 months in those who did not.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab6\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 6\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eSVR rates in the recurrent patients.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"8\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003ecopegus, pegasys\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003emavıret\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eharvoni\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003erıbavirin+\u003c/p\u003e\u003cp\u003esovosfobir\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c7\"\u003e\u003cp\u003epegasy, ribavirin, interferon\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c8\"\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eSVR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2 (66.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (100)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e31 (96.9)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e4 (80.0)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e0 (0)\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003e0.066\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1 (33.3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0 (0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1 (3.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e1 (20.0)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e2 (100)\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eSVR\u003c/p\u003e\u003cp\u003e3 mo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2 (66.7)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (100)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e28 (87.5)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e3 (60.0)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e0 (0)\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003e0.015\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1 (33.3)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0 (0)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e4 (12.5)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e2 (40.0)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e2 (100)\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eSVR\u003c/p\u003e\u003cp\u003e6 mo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2 (66.7)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (100)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e31 (96.9)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e4 (80.0)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e0 (0)\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003e0.002\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1 (33.3)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0 (0)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1 (3.1)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e1 (20.0)\u003csup\u003ea,b\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e2 (100)\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTotal\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e3 (6.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (14.3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e32 (65.3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e5 (10.2)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e2 (4.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e49 (100)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"8\"\u003e*Superscript letters indicate statistical significance between column proportions\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd colspan=\"8\"\u003e** Data are presented as n (%)\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eBefore DAA ,Zekry A. et all reported in their study of 182 patients with HCV, 3 ,5 year survival rates after LT were reported as 85%, 76%, respectively (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). In a study by Bonaccorsi-Riani E et al., 3-month and 1- and 5-year patient survival rates were 100%, 93% and 76%, respectively (7 ). In a study by Kim JM et al., the 1, 3, and 5 year cumulative patient survival rates were 78.8%, 75.3%, 73.1%. The same study showed that recipient age\u0026thinsp;\u0026ge;\u0026thinsp;60 years, deceased donor liver transplantation, biopsy-proven acute rejection and cyclosporine use, were independent prognostic factors for mortality (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). In HCV patients, the 5-year patient survival rate after transplantation was reported to be 76% in the United Network for Organ Sharing Database and 65% in the European Liver Transplant Registry (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). Recently, a nationwide live donor liver transplantation study in Japan reported 72% for a 5-year patient survival rate(\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). In the current study, the 1, 3, 5 ,10-year survival rates were 95.7%, 88.3%, 82.2% and 75%, respectively. We did not detect any significant factors affecting survival rates. After DAA Lim N reported 6,12,24 months HCC-free survival were 96.2, 96.2, and 78.8% in the DAA group, (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). In a study designed by Kauffman the median follow-up after LT was 55 months, the graft survival was 100%. at one and three years. Fifty-six patients received DAA after the LT with 98% SVR-12.( 12). Arora et all.. reported One-year patient survival and liver graft among HCV LT improved in DAA era (90% vs. 86%, 92% vs. 88%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.0001).(\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e). Our findings suggest that post-transplant survival rates are satisfactory when compared with previous studies. Additionally, our results suggest that LT should be considered when necessary in this patient group.\u003c/p\u003e\u003cp\u003eDetecting HCV recurrence early is important in terms of early initiation of treatment and good response in patients with recurrence. Successful treatment of recurrent HCV is associated with improved overall survival and reduced liver-related mortality(\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e). In our study, the recurrence rate was 50%. When we analyzed which factors affected recurrence, it was found that pre-transplant HCV-RNA positivity and pre-transplant HCV treatment had a statistically significant effect. In the study conducted by Kim JM, the recurrence rate was 57.4% (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). Burra P and colleagues reported that histological recurrence developed in 80% of patients, cirrhosis in 30%, and fibrosing cholestatic jaundice in 2\u0026ndash;5% within 5 years after transplantation,. In the same study,donor and recipient characteristics, viral status, surgical procedure and immunosuppression regimen applied were found to be associated with recurrence (\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e). Samonakis et al. reported that immunosuppression is an important factor for accelerated HCV recurrence (\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e). Terrault et al. reported that reinfection of the graft with HCV is universal in all HCV rNA PCR positif patients at transplantation, and the progression of fibrosis has been reported to be faster compared to patients who hadn\u0026rsquo;t transplantation (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). It was determined that pre-transplant viral load was a significant factor related to recurrence. Therefore, our results suggest that pre-transplant viral load plays an important role in post-transplant HCV recurrence in our study.\u003c/p\u003e\u003cp\u003eAfter the introduction of direct-acting antivirals (DAAs) in 2013 significant advances have been made in the treatment of HCV (improved efficacy,shorter treatment,good tolerability).(\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e)\u003c/p\u003e\u003cp\u003eIn this study, of the treatments given after transplantation to patients with recurrence, the highest rate of SVR24 (100%) was achieved with (100 mg glecaprevir \u0026minus;\u0026thinsp;40 mg pibrentasvir) treatment. Other treatment rates were 96.6% with \u003cb\u003e(\u003c/b\u003eledipasvir- sofosbuvir) 80% with sofosbuvir\u0026thinsp;+\u0026thinsp;ribavirin and 66.7% with (peginterferon alfa-2a), respectively. SVR24 was achieved in 44 of 49 patients (89.7%). The median of recurrence was 18.3 months. Before DAA ,Kim JM et al. reported that patients with SVR had higher survival rates than patients without SVR, and there was no importnat difference in patient survival between the two groups (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). In a study by Verna et al., post-transplant SVR12 was 67% (\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e). Sofosbuvir and simeprevir combination was evaluated in 68 LT patients enrolled in the study of real-life HCV TARGET. The SVR12 rate was 90% and was more in cirrhotic patients (\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). Kwo et al. reported that in a study of 34 patients (Ombitasvir-ABT-450/, receiving dasabuvir), 33 of these patients achieved a 97% SVR at 12 and 24 weeks after treatment (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e). In another study, Choudhary et al. reported 89.4% rate at 68/76 patients achieved SVR at 12 weeks (\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e). 1730 patients treated with a sofosbuvir-based interferon-free combination reported 90% SVR in post-transplant patients in a systemic review(\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e). After DAA ,in a study fo Beinhardt s, A total of 62 OLT recipients received RBV-free treatment with second-generation DAA combinations,SVR12 was 97% (60/62 (\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e). In a study designed by Iacob S included 89 patients patients with genotype 1 (GT1) recurrent hepatitis C after LT, 13 patients received sofosbuvir/ledipasvir+/-ribavirin and seventy six received ombitasvir/paritaprevir/ritonavir\u0026thinsp;+\u0026thinsp;dasabuvir\u0026thinsp;+\u0026thinsp;ribavirin. VR was 100% and SVR12 was 97.7%. (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e)In CORAL-I study (\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e)the combination of OBV/PTV/r\u0026thinsp;+\u0026thinsp;DSV\u0026thinsp;+\u0026thinsp;RBV for 24 weeks was investigated in 34 LT recipients with GT1 infection and achieved 97% SVR12. The ALLY-1 study [16], combining sofosbuvir\u0026thinsp;+\u0026thinsp;daclatasvir\u0026thinsp;+\u0026thinsp;ribavirin (SOF\u0026thinsp;+\u0026thinsp;DAC\u0026thinsp;\u0026plusmn;\u0026thinsp;RBV), showed 94% SVR12 (30% patients with liver graft cirrhosis). The Italian Compassionate use of Sofosbuvir (ITACOPS) [27] showed a 86.7% SVR rate at SOF/RBV treatment and 98.3% in patients receiving SOF/RBV for 24 weeks, when simeprevir or DAC was added. In a study designed by Liu 226 patients were divided in too two groups, pre (Group A) and post (Group B) 2014 to reflect the introduction of DAAs. The rate of SVR at 2 years of was 86.7% in group B and 15.4% group A.(28).\u003c/p\u003e\u003cp\u003eOur findings suggest that 100 mg glecaprevir \u0026minus;\u0026thinsp;40 mg pibrentasvir therapy is the most effective treatment for post-transplant relapse. Our results also show that sofosbuvir-based regimens are very effective treatments. There was no important difference in survival rates between those with and without recurrence. This finding also indicates that antiviral treatments are very effective in patients had recurrence after transplantation.\u003c/p\u003e\u003cp\u003eIn our study long-term results of relapsed patients were as follows: two patients (4.1%) were re-transplanted, three patients (6.1%) developed cirrhosis or graft failure, five patients (10.2%) developed fibrosing cholestatic hepatitis and four patients (8.2%) developed rejection. Burra P et al. reported that 30% of relapsed patients developed cirrhosis and 2%\u0026ndash;5% developed fibrosing cholestatic jaundice (\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e). Dumortier reported an estimated incidence of HCV-related fibrosing cholestatic jaundice after LT of 2%\u0026ndash;14% ( 29). Our findings suggest that the most common long-term problem in patients had recurrent HCV after transplantation is fibrosing cholestatic hepatitis.\u003c/p\u003e\u003cp\u003eFactors limiting our study were that patients came from different cities, which prevented us from accessing some information before and after transplantation.\u003c/p\u003e\u003cp\u003eIn conclusion, our findings suggest that survival rates after LT in HCV patients are satisfactory. In addition, our results suggest that although the recurrence rate after transplantation is high, with effective treatments, patients with recurrence have a long survival time similar to patients without recurrence.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eDAAs :direct-acting antivirals\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;LT: \u0026nbsp; \u0026nbsp; \u0026nbsp;liver transplantation\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eHCC:hepatocellular carcinoma\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eALT :alanine transaminase\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eSVR:sustained virological response\u0026nbsp;\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEA participated in data analysis and interpretation and article drafting. EA,MH,YB participated in data analysis and interpretation and article drafting. SY,VI,EA participated in data analysis and interpretation and article drafting. MA,HGG participated in data analysis and interpretation and in critically revising the manuscript for important intellectual content. EA,MH participated in the study design, data analysis and interpretation and gave final approval for publication. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets used and/or analysed during the current study available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was conducted according to the principles expressed in the Declaration of Helsinki and approved by the Ethics Committee of Inonu University in line with the Declaration of Helsinki (19-03-2024**2024/5697). Information an Informed consent was obtained from all patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo potential conflict of interest was reported by the author.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eG\u0026ouml;kahmetoğlu S, Polat C, Atalay MA, Sezgin GC, Erg\u0026ouml;r G, Aygen B, G\u0026uuml;rsoy Ş, Abacıoğlu YH. Healthcare-Related HCV Genotype 4d Infections in Kayseri, Turkey. Turk J Gastroenterol. 2022 Nov;33(11):964-970. doi: 10.5152/tjg.2022.21822. PMID: 36098364; PMCID: PMC9797710.\u003c/li\u003e\n\u003cli\u003eAkarca US, Unsal B, Sezgin O, Yalcin K, Akdogan M, Gonen C, Gunduz F, Ozenirler S, Sonsuz A, Dincer D, Tekin SB, Yucel I, Akbulut H, Alkım C, Ozyilkan O, Baygul A, Cevik ZM, Idilman R, Study Group OBOKR. Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study. Turk J Gastroenterol. 2021 Dec;32(12):1019-1028. doi: 10.5152/tjg.2021.201171. PMID: 34876392; PMCID: PMC8975510\u003c/li\u003e\n\u003cli\u003eMartinello M, Solomon SS, Terrault NA, Dore GJ. Hepatitis C. Lancet. 2023 Sep 23;402(10407):1085-1096. doi: 10.1016/S0140-6736(23)01320-X. PMID: 37741678.)\u003c/li\u003e\n\u003cli\u003eBerenguer M, Liver transplant 2002;8:S14.\u003c/li\u003e\n\u003cli\u003eWatt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug;9(8):1707-13. doi: 10.1111/j.1600-6143.2009.02702.x. Epub 2009 Jun 16. PMID: 19538491.\u003c/li\u003e\n\u003cli\u003eZekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, Gane EJ, McCaughan GW; Australian and New Zealand Liver Transplant Clinical Study Group. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl. 2003 Apr;9(4):339-47. doi: 10.1053/jlts.2003.50063. PMID: 12682883.\u003c/li\u003e\n\u003cli\u003eBonaccorsi-Riani E, Sempoux C, Piette N, Julliard O, Kabamba B, Ciccarelli O, Roggen F, De Reyck C, Hassoun Z, Lerut J. Impact of steroid-avoidance immunosuppression on long-term outcome after liver transplantation for HCV cirrhosis: the need for well documented long-term follow-up. Acta Gastroenterol Belg. 2012 Dec;75(4):411-8. PMID: 23402084.\u003c/li\u003e\n\u003cli\u003eKim JM, Lee KW, Song GW, Jung BH, Lee HW, Yi NJ, Kwon CH, Hwang S, Suh KS, Joh JW, Lee SK, Lee SG. Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study. Ann Surg Treat Res. 2016 Jan;90(1):36-42. doi: 10.4174/astr.2016.90.1.36. Epub 2015 Dec 29. PMID: 26793691; PMCID: PMC4717607.\u003c/li\u003e\n\u003cli\u003eSingal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95:755\u0026ndash;760. [PubMed] [Google Scholar][Ref list]\u003c/li\u003e\n\u003cli\u003eAdam R, Karam V, Delvart V, O\u0026apos;Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR) J Hepatol. 2012;57:675\u0026ndash;688. [PubMed] [Google Scholar][Ref list]\u003c/li\u003e\n\u003cli\u003eLim N, Singh D, Jackson S, Lake JR. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy. Gastrointest Tumors. 2020 Oct;7(4):134-143. doi: 10.1159/000510341. Epub 2020 Sep 14. PMID: 33173777; PMCID: PMC7590751.\u003c/li\u003e\n\u003cli\u003eKauffman-Ortega E, Ruiz-Manriquez J, Olivas-Martinez A, Campos-Murgu\u0026iacute;a A, Flores-Garc\u0026iacute;a NC, M\u0026aacute;rquez-Guill\u0026eacute;n E, L\u0026oacute;pez-Y\u0026aacute;\u0026ntilde;ez S, S\u0026aacute;nchez-\u0026Aacute;vila F, Toapanta-Yanchapaxi L, Paez-Zayas VM, Garc\u0026iacute;a-Ju\u0026aacute;rez I. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort. Arch Med Res. 2021 Oct;52(7):713-718. doi: 10.1016/j.arcmed.2021.04.003. Epub 2021 May 7. PMID: 33966917.\u003c/li\u003e\n\u003cli\u003eArora SS, Axley P, Ahmed Z, Satapathy SK, Wong R, Kuo YF, Singal AK. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study. Transpl Int. 2019 Aug;32(8):854-864. doi: 10.1111/tri.13424. Epub 2019 Mar 26. PMID: 30866110.\u003c/li\u003e\n\u003cli\u003eGuillouche P, Feray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther. 2011;33:163\u0026ndash;174. [PubMed] [Google Scholar][Ref list]\u003c/li\u003e\n\u003cli\u003eBurra P, De Martin E, Zanetto A, Senzolo M, Russo FP, Zanus G, Fagiuoli S. Hepatitis C virus and liver transplantation: where do we stand? Transpl Int. 2016 Feb;29(2):135-52. doi: 10.1111/tri.12642. Epub 2015 Aug 11. PMID: 26199060.\u003c/li\u003e\n\u003cli\u003eSamonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol. 2012 Apr;56(4):973-83. doi: 10.1016/j.jhep.2011.06.031. Epub 2011 Sep 29. PMID: 21963518.\u003c/li\u003e\n\u003cli\u003eTerrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown Jr RS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007;13:122\u0026ndash;129.\u003c/li\u003e\n\u003cli\u003e(\u0026Ccedil;ekin AH, G\u0026uuml;ner R, \u0026Ccedil;ağkan İnkaya A, Oğuz D, \u0026Ouml;zdemir O, Tabak \u0026Ouml;F. Modeling the Health Economic Burden of Hepatitis C Virus Infection in Turkey: Cost-Effectiveness of Targeted Screening. Turk J Gastroenterol. 2023 Oct;34(10):1062-1070. doi: 10.5152/tjg.2023.22749. PMID: 37565793; PMCID: PMC10645295.)\u003c/li\u003e\n\u003cli\u003eVerna EC, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, Fox AN, Dove LM, Brown RS. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver Int. 2015;35:510\u0026ndash;517. [PubMed] [Google Scholar] [Ref list]\u003c/li\u003e\n\u003cli\u003eSulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim KJ, Morelli G, Feld JJ, Brown RS, Frazier LM, et al. Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + Ribavirin in Patients with Genotype 1: Interim Results of a Prospective, Observational Study. Hepatology. 2014;60(S1):660A. [Google Scholar] [Ref list]\u003c/li\u003e\n\u003cli\u003eKwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR Jr, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18;371(25):2375-82. doi: 10.1056/NEJMoa1408921. Epub 2014 Nov 11. PMID: 25386767.\u003c/li\u003e\n\u003cli\u003eChoudhary NS, Saigal S, Gautam D, Saraf N, Rastogi A, Goja S, Bhangui P, Soin AS. Efficacy And Safety of Sofosbuvir Based Regimens For Treatment of Hepatitis C Recurrence After Living Donor Liver Transplantation: An Experience From India. J Clin Exp Hepatol. 2018 Jun;8(2):121-124. doi: 10.1016/j.jceh.2017.08.004. Epub 2017 Sep 1. PMID: 29892173; PMCID: PMC5992320.\u003c/li\u003e\n\u003cli\u003eQu Y., Guo Y., Li T. Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients. J Gastroenterol Hepatol. 2017;32:740\u0026ndash;748.[PubMed] [Google Scholar] [Ref list]\u003c/li\u003e\n\u003cli\u003eBeinhardt S, Al-Zoairy R, Kozbial K, St\u0026auml;ttermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, Graziadei I, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver Int. 2018 Jul;38(7):1188-1197. doi: 10.1111/liv.13652. Epub 2018 Jan 31. PMID: 29197145\u003c/li\u003e\n\u003cli\u003eIacob S, Cerban R, Pietrareanu C, Ester C, Iacob R, Gheorghe C, Popescu I, Gheorghe L. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation. J Gastrointestin Liver Dis. 2018 Jun;27(2):139-144. doi: 10.15403/jgld.2014.1121.272.100. PMID: 29922758\u003c/li\u003e\n\u003cli\u003eKwo PY, Mantry PS, Coaldey E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371:2375-2382 Kwo PY, Mantry PS, Coaldey E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371:2375-2382 oi:10.1056/NEJMoa140892\u003c/li\u003e\n\u003cli\u003eCarrai P, Morelli C, Cordone G, et al. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transpl Int 2017;30:1253-1265. doi:10.1111/tri.13018\u003c/li\u003e\n\u003cli\u003eLiu A, Angirekula M, Elhawary A, Mara K, Kulai T, Leise M, Watt KD. Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response. Clin Transplant. 2023 Oct;37(10):e15050. doi: 10.1111/ctr.15050. Epub 2023 Jun 17. PMID: 37329298.\u003c/li\u003e\n\u003cli\u003eDumortier J, Boillot O, Scoazec JY. Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. World J Gastroenterol. 2014 Aug 28;20(32):11069-79. doi: 10.3748/wjg.v20.i32.11069. PMID: 25170196; PMCID: PMC4145750.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-gastroenterology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bmge","sideBox":"Learn more about [BMC Gastroenterology](http://bmcgastroenterol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bmge/default.aspx","title":"BMC Gastroenterology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Hepatitis C virus, liver transplantation, recurrence","lastPublishedDoi":"10.21203/rs.3.rs-7629220/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7629220/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eAim\u003c/h2\u003e\u003cp\u003eHCV is a major indication for liver transplantation (LT) in Europe, America, Australia and Japan. Virological recurrence after HCV-related LT is almost inevitable.We aimed to presantation long-term outcomes of patients LT due to hepatitis C.\u003c/p\u003e\u003ch2\u003eMaterials and Methods\u003c/h2\u003e\u003cp\u003eWe included 98 patients who had LT because of HCV-related liver disease at XXXXXXX University Faculty of Medicine between 2007 and 2022. The survival and recurrence rates of HCV patients and the factors that affected survival and recurrence were investigated. Treatment responses, long-term outcomes in patients had recurence were also analyzed.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003eThe average post-transplant survival time of 98 patients who had LT due to HCV was 11.91\u0026thinsp;\u0026plusmn;\u0026thinsp;0.56 years, and 1, 3, 5,10-year survival rates were 95.7%, 88.3%, 82.2% ,75%.The HCV recurrence rate after transplantation was 50%. HCV-RNA positivity and HCV treatment before transplantation were statistically significant factors affecting recurrence. In recurrent patients, the highest rate of sustained virological response at 6 months (100%) was achieved with Maviret (100 mg glecaprevir \u0026minus;\u0026thinsp;40 mg pibrentasvir). We didn\u0026rsquo;t find any difference in survival rates between those with and without recurrence.Our findings suggest that survival rates after LT in HCV patients are satisfactory.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e\u003cp\u003eIn addition, these results suggest that although the recurrence rate after transplantation is high, with effective treatments, patients with recurrence have a long survival time similar to patients without recurrence.\u003c/p\u003e","manuscriptTitle":"Long-term outcomes of patients with Hepatitis C virus-related liver transplantation in a high-volume transplant center","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-09 13:49:20","doi":"10.21203/rs.3.rs-7629220/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-10-16T09:51:01+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-16T09:14:18+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-12T01:31:00+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-09T10:05:56+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"168799947593528656285196380480446388429","date":"2025-10-01T05:55:32+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"293289295644818615888931202598399477870","date":"2025-10-01T04:24:44+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"21006172996339097515048933471900963243","date":"2025-09-28T18:01:44+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-09-28T12:06:10+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2025-09-25T21:27:02+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-09-24T15:37:15+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-09-24T15:37:03+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Gastroenterology","date":"2025-09-16T10:20:07+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-gastroenterology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bmge","sideBox":"Learn more about [BMC Gastroenterology](http://bmcgastroenterol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bmge/default.aspx","title":"BMC Gastroenterology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1423c6f5-bc12-4076-a81a-5361f174dc55","owner":[],"postedDate":"October 9th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2026-05-04T15:59:09+00:00","versionOfRecord":{"articleIdentity":"rs-7629220","link":"https://doi.org/10.1186/s12876-026-04678-9","journal":{"identity":"bmc-gastroenterology","isVorOnly":false,"title":"BMC Gastroenterology"},"publishedOn":"2026-04-29 15:57:13","publishedOnDateReadable":"April 29th, 2026"},"versionCreatedAt":"2025-10-09 13:49:20","video":"","vorDoi":"10.1186/s12876-026-04678-9","vorDoiUrl":"https://doi.org/10.1186/s12876-026-04678-9","workflowStages":[]},"version":"v1","identity":"rs-7629220","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7629220","identity":"rs-7629220","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}